Using Insulin in the Primary Care Setting: Interactive Cases
|
|
- Norman Wilcox
- 6 years ago
- Views:
Transcription
1 Using Insulin in the Primary Care Setting: Interactive Cases Irl B. Hirsch, MD University of Washington School of Medicine Dualities (Nov, 2011) Research Grants: sanofi-aventis, Novo Nordisk, Halozyme, Mannkind Consulting: Cellnovo, Roche, Johnson & Johnson, Abbott Diabetes Care Teaching Point 1, Case 1 After 1 year of attempted weight loss and rising A1C levels since his diagnosis, Mr. Henry, 51 years-old, agrees it is time to start insulin. His BMI is 28 kg/m 2, his weight is 80 kg, his A1C is 8.8%, and he is currently receiving metformin, glipizide, and sitagliptin. Decision point 1- WHICH INSULIN/INSULIN REGIMEN DO YOU START? 1
2 Treat-to-Target Trial Change of A1c with systematic titration of basal insulin Mean A1c % Glargine NPH % 7% Weeks of treatment Riddle MC et al. Diabetes Care 2003;26: Consistent results using the Treat-to-Target method with glargine as basal insulin HbA 1C (%) T-T-T 1 n = 367 Baseline INSIGHT 2 n = Riddle M et al. Diabetes Care 2003;26: Gerstein HC et al. Diabetes Med 2006;23: Bretzel RG et al. Lancet 2008;371: Yki-Järvinen H et al. Diabetes Care 2007;30: Schreiber SA et al. Diabetes Obes Metab 2007;9:31 APOLLO 3 n = 174 Study end Teaching Point 1: Most people can reach an A1C < 7% with basal insulin alone with baseline A1C levels in the mid-8s INITIATE 4 n = 58 Schreiber 5 n = 12,216 Baseline A1c affects results of basal insulin Rx 2193 patients with 24 weeks systematically titrated glargine added to OAD A1c change from baseline % of patients attaining <7% A1c 75 TEACHING POINT 632: Final A1C (with -1.6 basal insulin) 34 is -2.0 dependent -2.6on baseline A1C! 75% of participants with baseline A1c <8% attained 7% Riddle MC et al. Diabetes 2009;58(Suppl 1): A125 2
3 Baseline A1c does not affect hypoglycemia risk 2193 patients with 24 weeks systematically titrated glargine added to OAD Hypoglycemia confirmed <3.9 mmol/l (70 mg/dl) Hypoglycemia requiring assistance 50% 1.5% < Titration of insulin was stopped at appropriate levels of risk Riddle MC et al. Diabetes 2009;58(Suppl 1): A125 Back to Mr. Henry 15 units of insulin glargine is started, and over the next 4 months his dose was titrated to 80 units daily The metformin, glipizide, and sitagliptin remained unchanged; on glargine he has gained 3 kg After being on the 80 unit dose for 8 weeks, 5 months after starting the insulin, his A1C is 7.3%. Fasting glucose levels are generally in the mg/dl range. What now? A) Bump glargine to 90 u; B) Split glargine to 40 u BID; C) SMBG to determine prandial insulin needs; D) add pioglitazone; E) wait another 4 weeks to recheck the A1C What About Dose Response to Insulin Glargine in Obese Patients? 20 subjects with type 2 diabetes (A1C 8.3%, BMI 36 kg/m 2 ) injected single injections of insulin glargine into abdomen at 0, 0.5, 1.0, 1.5, and 2.0 units/kg body weight 26-hour euglycemic clamp studies, so conclusions longer than this time period were not possible Wang Z. Diabetes Care. 2010;33:
4 Glucose Infusion Rates (GIRs) for Different Glargine Doses Injected into Abdomen TEACHING POINT 1.0, 1.5, and 2.0 3: units/kg although > GIR it is than 0.5 units/kg, but not than each other! possible duration of 1.5 insulin action is 1.0 units/kg units/kg 0.5 units/kg 2.0 units/kg prolonged with increasing doses of glargine, there is no difference in insulin action the 24 h after injection once dose is > 1.0 u/kg placebo WAIT A MINUTE! Mr. Henry now has a BMI of 29.5 kg/m 2, uses an insulin pen for his insulin glargine-and he needs all of his scripts renewed. What size pen needles do you write for? A) 4 mm 32 G B) 5 mm 31 G C) 8 mm 31 G D) 12.7 mm 29 G Nano Mini Short Original Distribution of Skin Thickness Values (in mm) by Body Site and BMI 1. Small differences within each body site: obese higher (P<0.001) In perspective: a 10 kg/m 2 change in BMI accounts for a 0.2 mm change in ST 2. Mulitvariate analysis between sites and genders (P<0.001) but not age (NS) 2. Thigh lowest ST values 3. Greatest difference thigh/buttocks 0.6 mm Gibney MA et al: Curr Med Res Opin Jun;26(6):
5 Estimates of Intramuscular (IM) Injection Risk from ST/SCT Data* Pen Needle Length (mm) IM (%) 4 mm mm mm mm mm 45.0 *Assume a 90-degree insertion without pinch-up. All injection sites combined (n = 1,208) Gibney MA et al: Curr Med Res Opin Jun;26(6): Study Conclusions: 4 mm and 5 mm vs. 8 mm Insulin Needles N= 328 Equivalent glycemic control REGARDLESS of BMI No differences in hypoglycemia between needle lengths Strong preference for shorter needles Ease of use, pain, overall preference Hirsch LJ. Curr Med Res Opin. 2010;26: Back to Mr. Henry A1C=7.3%, injecting 80 units of insulin glargine with 4 mm needle q HS; also receiving maximum dose metformin, glipizide, sitagliptin He is asked to increase testing to 2-3X/day Tries to limit carbohydrates to no more than 60 grams/meal (met with nutritionist) 5
6 SMBG RESULTS B FAST LUNCH DINNER HS 0300 h MON TUES WED THURS FRI SAT 142 SUN NOW WHAT? What to do with the glargine? What to do with prandial insulin? What to do with metformin, glipizide, and sitagliptin? What s Next? Glargine is reduced to 70 units q HS Insulin aspart is started at dinner, 10 units (10-15 min prior to dinner) Correction dose for any pre-meal BG: ISF 30 above unit units units units units units Sitagliptin is stopped! 6
7 NOW WHAT TO SUGGEST? B FAST LUNCH DINNER HS 0300 MON TUE WED THU G G G G Why the Interest In Glycemic Variability? Experimental data suggests an increase in oxidative stress and activation of inflammation May be involved with pathogenesis of vascular complications For those on insulin high variability predicts severe hypoglycemia A marker of insulin deficiency and poor matching of prandial insulin to carbohydrate load Which Patient Has More Variable Fasting Glucose Data? Joe: HbA1c = 6.5%; on liraglutide Mean = 123 mg% Mary: HbA1c = 6.5%; on metformin Mean = 123 mg% SD = 51 SD = 77 7
8 Standard Deviation Our clinically available measurement of glycemic variability Many other statistical analysis are available but correlation will be with CGM and outcomes, not SMBG Can determine both overall and time specific SD Need sufficient data points Minimum 5 but prefer 10 Calculation To Determine SD Target SD X 2 < MEAN (T1DM) Ideally SD X 3 < mean Significance of a High SD Insulin deficiency (especially good with fasting blood glucose) Poor matching of calories (especially carbohydrates) with insulin Giving mealtime insulin late (or missing shots completely) Erratic snacking Poor matching of basal insulin, need for CSII? CGM? 8
9 Caveats of the SD Need sufficient SMBG data Low or high averages makes the 2XSD<mean rule irrelevant Other Tricks To Reduce GV Enough testing Don t over-treat the lows! Reduce carbs Pramlintide/exenatide Lag times Timing of Rapid-Acting Analog Insulin Injection Alters PPG in Type 1 Diabetes Mellitus BG Level (mg/dl) Insulin Lispro Injection-Meal Interval (minutes) 30 m 15 m 0 m +15 m BG Level (mg/dl) Insulin Glulisine Injection-Meal Interval (minutes) 20 m 0 m +20 m kcal/kg breakfast Minutes 36 Standardized breakfast Minutes Rassam AG, et al. Diabetes Care. 1999;22: Cobry E, et al. Diabetes Technol Ther. 2010;12:
10 Now Back to Mr. Henry He is currently taking insulin glargine, 50 u q HS with premeal insulin aspart, 2-5 u ac breakfast, units ac lunch and dinner with an insulin sensitivity factor of 25 (1 unit corrects 25 mg/dl) above 150 before meals, 200 at HS. A1C = 6.7% What does the meter download suggest? Mr. Henry s Download Statistics Summary (30 days) Frequency of testing = 3.2X/day Fasting mean/sd: AC lunch mean/sd: AC dinner mean/sd HS mean/sd: Overall: Conclusions: 1. Still too much basal insulin 2. Needs help with dosing at dinner (missing doses?) 3. Still making lots of insulin! 4. Need to look at downloaded logbook to understand specifics (insulin not yet downloadable) and if ISF is correct Teaching Point 4 Downloading of glucose data is extremely helpful to see patterns not otherwise noted for those checking more than 2X/day. These downloads will become more accessible over the next few years with the use of tablets and smartphones 10
11 Mr. Spar Tan A 56 year-old mildly mentally retarded Caucasian man presents with a random blood glucose found to be 435 mg/dl. There is no family history of diabetes. He lives with his brother who mentions nocturia and 10 pound weight loss over the past month. The patient s only complaint is erectile dysfunction. Exam is significant for a BMI of 32 kg/m 2, BP 155/95, HR 88, mild acanthosis nigricans, normal fundi and vibratory sensation on his great toes. Mr. Spar Tan, cont Glucose 435 mg/dl, all other electrolytes WNL except sodium of 133. HbA1C 14.0% (normal 4-6%) Urine ketones: negative What would you suggest at this time? A) Begin combination glipizide/pioglitazone B) Begin basal-bolus insulin C) Begin basal insulin alone D) Begin twice daily NPH/regular Teaching Point(s) 5 Type 1 diabetes can occur at any age Type 1 diabetes can occur in obese patients While acute presentation can be seen in type 2 diabetes, it is more common in type 1 diabetes and while sorting out the specific etiology of the diabetes, initiating insulin is never the wrong therapy The best two auto-antibodies for this age group is GAD65 and IA-2 (ICA-512) 11
12 Mr. Bill Dog Ms. Duck is a 54 year-old woman who will be having a pancreatectomy. What will you tell her she will require for insulin therapy after his surgery? A.Basal insulin alone B.Pre-mix insulin, 0.5 u/kg C.Basal-bolus insulin, 0.7 u/kg D.Basal-bolus insulin, 0.25 u/kg E. GLP-1 receptor agonist Teaching Point 6 Pancreatectomized patients are glucagon deficient, are very insulin sensitive, and are prone to severe hypoglycemia Mr. Grass Lee Mr. Lee, a convicted tax evader from Iowa, now is an 81 year-old nursing home patient. He has a known 10 year history of type 2 diabetes and suffers from Alzheimer s Disease and heart failure from a previous MI In the nursing home over the past year he has lost 12 pounds. For his diabetes he receives glyburide 10 mg BID His A1C is 10.4%. BID glucose testing shows all levels between 220 and 280 mg/dl Other lab: creatinine 1.4, BUN 25, LDL-C 59 12
13 Mr. Lee (cont) What to do now? A) Nothing B) Add a GLP-1 agonist C) Add a thiazolidinedione D) Add basal insulin E) Begin basal-bolus insulin therapy Teaching Point 7 Many elderly patients become severely insulin deficient and often insulin is required to prevent severe symptoms, most notably falling at night from using the bathroom Mrs. PIA You receive a call at 5pm on a Friday from Mrs Pia that she needs a new prescription for insulin syringes. She takes 60 units of insulin detemir at bedtime and insists she uses a short insulin needle What kind of insulin syringe to you call for her? 13
14 Teaching Point 8 Insulin syringes come in 3 volumes: 1cc (100 units) ½ cc (50 units) and 0.3 cc (30 units) Mr. Fred I. Zone A 55 year-old man with well-controlled type 2 diabetes treated with metformin is started on prednisone, 40 mg/day for severe asthma. Random fingerstick glucose his second day after starting the prednisone is 355 mg/dl What insulin regimen would serve Mr. Zone the best? A) bedtime NPH B) bedtime glargine C) BID 70/30 premix D) premeal lispro E) bedtime glargine, premeal lispro Tough Case (if time!) A 53 year-old man with 5 years of type 2 diabetes presents with a HbA1c of 9.9%. He and his wife are frustrated in that he limits his carbohydrate and exercises 6X/week. His BMI is 27 and his exam is unremarkable other than he wears hearing aids. His insulin dose is 60 units of insulin glargine twice daily and premeal insulin lispro units before meals. He cramps with metformin and pioglitazone had no impact on his glucose levels. What would you do next? 14
15 Conclusions Our insulins are far from perfect, but if we can be creative our patients can usually do well Thank You! 15
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More information5/18/2010. History of 1,5 Anhydroglucitol (1,5 AG) Glucose Variability & Pattern Management: Way Beyond Logbooks. Normal Renal Glucose Handling
Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA Normal Renal Handling 180 g of glucose is filtered each day Virtually all glucose reabsorbed
More informationGlucose Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA
Glucose Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA 1 Normal Renal Glucose Handling 180 g of glucose is filtered each day Virtually all
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationLET S TALK INSULIN THE BASICS
LET S TALK INSULIN THE BASICS AUTHOR S DISCLOSURES Contracted for program development for Lifescan Canada Speaker for Lifescan, Lilly, BI, Consultant for Lilly, Janssen, Novo Nordisk, Lifescan Canada OBJECTIVES
More informationEvolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk
Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk Harvard/Joslin Primary Care Congress for Cardiometabolic Health 2013 Richard S. Beaser, MD Medical Executive
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationAnalyzing Glucose Data
Analyzing Glucose Data Objectives Identify when insulin needs to be adjusted Identify pattern of high and low BGs Provide sources of information on how to adjust insulin Titrate insulin doses based on
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationComplete this CE activity online at ProCE.com/InsulinPart2
Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationType 2 Diabetes Performance Improvement Initiative: Chart Reviews. Lara Zisblatt Boston University School of Medicine Boston, MA
Type 2 Diabetes Performance Improvement Initiative: Chart Reviews Lara Zisblatt Boston University School of Medicine Boston, MA Participants in the Program 487 people registered 217 people started the
More informationParticipants in the Program
Type 2 Diabetes Performance Improvement Initiative: Chart Reviews Lara Zisblatt Boston University School of Medicine Boston, MA Participants in the Program 487 people registered 217 people started the
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationInsulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology
Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, 2018 10:30 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US.
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationT2DM and Need for Insulin. Insulin Pharmacokinetics. When To Start Insulin in T2DM. FDA-approved Insulins for Subcutaneous Injection
Plasma Insulin Levels Patients Requiring Insulin (%) Effective Use of Insulin in the Primary Care Practice: Insulin Therapy Initiation, Intensification, and the Insulinizing Complex Patients with T2DM:
More informationCase Study: Competitive exercise
Case Study: Competitive exercise 32 year-old cyclist Type 1 diabetes since age 15 Last HbA1 54 No complications and hypo aware On Humalog 8/8/8 and Levemir 15 Complains about significant hypoglycaemia
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationIndividualizing Therapy int2dm With Insulin
Individualizing Therapy int2dm With Insulin Etie Moghissi, MD, FACP, FACE Clinical Associate Professor University of California, Los Angeles Los Angeles, California OBJECTIVES: At the conclusion of this
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationImportant Stuff. Basal Bolus What Adjustments? Pt weighs 80kg
Diabetes Boot Camp Class 4 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Special Insulin and Pattern Management Diabetes Education Services 1998-2015. All rights
More informationUsing and Interpreting Diabetes Data. Irl B. Hirsch, MD University of Washington
Using and Interpreting Diabetes Data Irl B. Hirsch, MD University of Washington Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas,
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationType 2 Diabetes Use of Insulin. Today 5/24/10. Robert J. Rushakoff, MD
Type 2 Diabetes Use of Insulin Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco robert.rushakoff@ucsf.edu Today Quick Year in Review Why do some patients need to take
More informationCHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationAll Things Insulin: Dosing, Monitoring, Titrating, Transitioning
All Things Insulin: Dosing, Monitoring, Titrating, Transitioning Target Audience: Pharmacists ACPE#: 0202-0000-18-052-L01-P Activity Type: Application-based Disclosures Stuart Haines declares that he has
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More informationPediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services
1.19.18 Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services DISCLOSURES 1. No financial incentives 2. Volunteer Positions 1. National Certification Board
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationApplications of Technologies to Your Patient. Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington
Applications of Technologies to Your Patient Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington Disclosures Consultant: Abbott Diabetes Care, Roche
More informationManagement: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018
Management: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018 Disclosures I have no Objectives Use a case-based format to discuss diabetes management pearls Discuss
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 1, 218 1:3 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US. About
More informationBackground: Brief review of epidemiology, diagnosis, classification and pathophysiology of diabetes mellistus.
Insulin Therapy in Diabetes Mellitus Part 1 Lekshmi T. Nair, MD, MHS Assistant Professor Department of Internal Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner
More informationSelf-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool
Self-Monitoring Blood Glucose () Pattern Recommendation: Basal Insulin Only (To Target) NPH or long-acting analogue, typically given at. at least as often as is being given. Optional, less frequent can
More informationInsulin Initiation, titration & Insulin switch in the Primary Care-KISS
Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda
More informationEmerging Challenges in Primary Care: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins
Emerging Challenges in Primary Care: 2018 Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins 1 Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine
More informationAdjusting Insulin Doses
Adjusting Insulin Doses Everyone with diabetes, including you, will need to adjust your insulin doses at some time. There are several reasons why a person may need an insulin adjustment. These reasons
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationSession 3: Insulin Strategies for Primary Care Providers: Addressing a Core Defect in Diabetes Learning Objectives
Session 3: Insulin Strategies for Primary Care Providers: Addressing a Core Defect in Diabetes Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin, and
More informationRole of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD
Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD International Diabetes Center and Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationBasal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January
Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals
More informationHarvesting Healthy Hemogobins: Optimal Management of A1c and Beyond. Carol H. Wysham, M.D Rockwood Clinic Spokane, WA
Harvesting Healthy Hemogobins: Optimal Management of A1c and Beyond Carol H. Wysham, M.D Rockwood Clinic Spokane, WA Diabetes: 21 Million and Climbing Estimated 15 million diagnosed + 6.2 million undiagnosed
More informationInsulin Therapies for T2DM
Insulin Therapies for T2DM Defects in T2DM Decreased insulin secretion Inefficient glucose uptake (skeletal muscles) Increased hepatic glucose production Decreased incretin effect Increased glucagon secretion
More informationManagement of Gestational Diabetes
Management of Gestational Diabetes A Diabetes risk assessment should be ascertained at the First prenatal visit. Low Risk: Early blood glucose screening is NOT routinely required if most of the following
More informationApplication of the Diabetes Algorithm to Patients
Application of the Diabetes Algorithm to Patients Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationInsulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination. Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM
Insulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM University of Mississippi School of Pharmacy Joshua J. Neumiller, Pharm.D., CDE, FAADE,
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSample Exam Questions
Disclaimer These are not validated questions. They have been created to enhance your learning and provide practice in reading and answering multiple choice questions. Some questions have been created to
More informationInsulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationDiabetic Emergencies DKA, HHS, Hypoglycemia. Disclosure. Learning Objectives
Diabetic Emergencies DKA, HHS, Hypoglycemia October 2018 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Disclosure Michael McDermott has no conflict
More informationDiabetes Care Publish Ahead of Print, published online June 1, 2009
Diabetes Care Publish Ahead of Print, published online June 1, 2009 Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human
More informationInsulin 301: Case, after case, after case
Insulin 301: Case, after case, after case Learning objectives By the end of this session, you will be able to : 1. List the 3 types of insulin, 3 insulin regimens and pros/cons of each 2. Select the regimen
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPhysiology of Normoglycemia
Case 1 45 year-old male patient seen at the clinic (Medicine). Workplace stress (financial analyst); occasionally goes jogging. Two-year duration of T2DM. No previous cardiovascular events. Coexisting
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationABFM Diabetes SAM Part 4
ABFM Diabetes SAM Part 4 37. A 55-year-old male with type 2 diabetes mellitus has a chronic history of reduced libido and erectile dysfunction. On examination you note hepatomegaly and mild testicular
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationDiabetes Technology for the Endocrinologist, Irl B. Hirsch, MD University of Washington
Diabetes Technology for the Endocrinologist, 2017 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia, Adocia,
More informationThe New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy
The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor of Pharmacy Practice Midwestern
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More information